US 8,894,994 B2 · Modified beta-lactamases and methods and uses related thereto

Abstract

The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

Claims17

Dependent claims

A beta-lactamase, comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO:

1 and a hydrophilic amino acid residue other than aspartic acid (D) at a position corresponding to position 276 according to Ambler classification, wherein:
the hydrophilic amino acid residue is asparagine (N) and
the beta-lactamase hydrolyzes ceftriaxone substantially more efficiently than a beta-lactamase of SEQ ID NO:
1 that has an aspartic acid (D) at a position corresponding to position 276 according to Ambler classification.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

14/047,882Filed 7 Oct 2013 · continuation

Priority

FI 2010557224 May 2010

Published

US 2014/0127785 A18 May 2014

Granted

25 Nov 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C12N 9/86
Acting on carbon to nitrogen bonds other than peptide bonds: acting on amide bonds in cyclic amides, e.g. penicillinase
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/4891
Preparations in capsules, e.g. of gelatin, of chocolate: coated capsules; Multilayered drug free capsule shells
A61K 31/43
Condensed with heterocyclic ring systems: compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring…

Family

PCT/FI2011/050450Parent of this continuation · filed 17 May 2011

US 2014/0127785 A1Pre-grant publication · published 8 May 2014

Application13/699,434Parent of this continuation

US 2013/0216622 A1Published application

US 9,034,602 B2Related patent

US 8,894,994 B2This patent

From the US filing history. Foreign family members aren’t listed.

Modified beta-lactamases and methods and uses related thereto

Life of this patent

Modified beta-lactamases and methods and uses related thereto

Life of this patent

Abstract

Claims17